The global aortic valve replacement market is anticipated to grow at a considerable CAGR of 11.2% during the forecast period. The new launches in the market along with increasing FDA approvals are contributing to the growth of the global market. Various companies such as Medtronic PLC, Boston Scientific Corp., Abbott Laboratories Inc., and others received approval for their advanced aortic heart valves as these companies can commercialize their products and gain a strong position in the market. For instance, in May 2021, Abbott announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk. With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve. Using Abbott’s industry-leading FlexNav delivery system, the Navitor TAVI system is the latest addition to the company’s comprehensive structural heart transcatheter portfolio that offers physicians and patients less invasive options to treat heart diseases.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/aortic-valve-replacement-market
In October 2021, JenaValve Technology, Inc., a developer, and manufacturer of transcatheter aortic valve replacement (TAVR) systems launched a Trilogy heart valve system in Europe. Trilogy is a transfemoral TAVR system approved for the treatment of aortic regurgitation (AR). In addition, the Trilogy system is CE Mark approved for aortic stenosis (AS), providing European physicians with dual-disease treatment capabilities. The first commercial implantation procedures, which included treatment of both AR and AS, took place at multiple centers in Germany.
In October 2021, MicroPort CardioFlow Medtech Corp. (CardioFlow Medtech) launched VitaFlow Liberty. The VitaFlow Liberty is a next-generation product for transcatheter aortic valve implantation (“TAVI”). The product, presented at China Structural Week 2021 and the 5th China International Structural Heart Disease Conference held in Beijing, Shanghai, Guangzhou, and Xi’an, drew the attention of experts in the field of structural heart disease and triggered discussions on the development of the TAVI procedure.
In August 2021, Medtronic announced the US Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve implantation (TAVI) system, the Evolut FX. Designed to enhance ease of use and provide greater precision and control throughout the procedure, the Evolut FX system maintains the hemodynamic and durability properties of the Evolut platform, while bringing product and procedure innovation to patients with symptomatic severe aortic stenosis, Medtronic said in a press release.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Disease
- By Device
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- including Abbott Laboratories, Boston Scientific Corp., Cardiosolutions, Inc., LivaNova, PLC, Medtronic, PLC, Micro Interventional Devices, Inc., MitrAssist Ltd., NVT AG, Koninklijke Philips N.V., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Aortic Valve Replacement Market Report Segment
By Disease
- Aortic Stenosis
- Aortic Regurgitation
By Device
- Mechanical Heart Valves
- Transcatheter Heart Valves
- Tissue Heart Valves
- Stented Bioprostheses
- Stentless Bioprostheses
- Sutureless Bioprostheses
- TAVI
By End-User
- Hospitals
- Ambulatory Surgical Centers
- Others (Academic Research Laboratories & Cardiac Catherization Laboratories)
A full report of Aortic Valve Replacement Market is available at: https://www.omrglobal.com/industry-reports/aortic-valve-replacement-market
Aortic Valve Replacement Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Abbott Laboratories
- Autotissue Berlin GmbH
- BioAlps Association
- Boston Scientific Corp.
- Cardiosolutions, Inc.
- Cryolife, Inc.
- Edwards Lifesciences Corp.
- HLT, Inc.
- JenaValve Technology Inc.
- LivaNova, PLC
- Medtronic, PLC
- Micro Interventional Devices, Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
